EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome

Doron Zahger, Gregory G Schwartz, Weiming Du, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Andrzej J Budaj, Rafael Diaz, Shaun G Goodman, J Wouter Jukema, Robert G Kiss, Robert A Harrington und 10 weitere

Journal of the American College of Cardiology · 2024-09 · 84 (11) · 994-1006

DOI: 10.1016/j.jacc.2024.06.035 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the American College of Cardiology, 2024-09. Verfasst von Doron Zahger und 21 weiteren Autor:innen. Beteiligte Einrichtung: Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel. Electronic address: dzahger@bgu…. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized, Triglycerides. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regeneron Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: It is unknown whether clinical benefit of proprotein convertase subtilisin/kexin type 9 inhibitors is associated with baseline or on-treatment triglyceride concentrations. OBJECTIVES: This study sought to examine relations between triglyceride levels and the effect of alirocumab vs placebo on cardiovascular outcomes using prespecified and post hoc analyses of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial. METHODS: Patients with recent acute coronary syndrome (ACS) (n = 18,924) and elevated atherogenic lipoproteins despite optimized statin therapy were randomized to alirocumab 75 to 150 mg or matching placebo every 2 weeks subcutaneously. Major adverse cardiovascular events (MACE) were examined in relation to continuous or dichotomous triglyceride concentrations. RESULTS: Median baseline triglyceride concentration was 129 mg/dL. In both treatment groups, a 10-mg/dL higher baseline concentration was associated with an adjusted MACE HR of 1.008 (95% CI: 1.003-1.013; P < 0.005). Baseline triglycerides ≥150 vs

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeAntibodies, Monoclonal, HumanizedTriglyceridesAgedFemaleHumansMaleMiddle AgedCardiovascular DiseasesDouble-Blind MethodPCSK9 InhibitorsTreatment Outcome

Stichwörter der Autor:innen

cardiovascular riskclinical triallipidsproprotein convertase subtilisin/kexin type 9 inhibitor

Substanzen

alirocumabAntibodies, Monoclonal, HumanizedPCSK9 InhibitorsTriglycerides

Autor:innen und Institutionen

  • Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel. Electronic address: dzahger@bgu.ac.il.
  • Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
  • CPC Clinical Research, Aurora, Colorado, USA; Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA; State University of New York, Downstate Health Sciences University, Brooklyn, New Y…
  • Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, New York, USA.
  • Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Förderung

  • Regeneron Pharmaceuticals Inc

Zitieren

APA

Zahger, D., Schwartz, G. G., Du, W., Szarek, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Jukema, J. W., Kiss, R. G., Harrington, R. A., Moriarty, P. M., Scemama, M., Manvelian, G., Pordy, R., White, H. D., Zeiher, A. M., Fazio, S., …, & ODYSSEY OUTCOMES Investigators (2024). Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome. Journal of the American College of Cardiology, 84(11), 994-1006. https://doi.org/10.1016/j.jacc.2024.06.035

Vancouver

Zahger D, Schwartz GG, Du W, Szarek M, Bhatt DL, Bittner VA, et al. Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome. Journal of the American College of Cardiology. 2024;84(11):994-1006. doi:10.1016/j.jacc.2024.06.035

BibTeX
@article{Zahger2024,
  author = {Zahger, Doron and Schwartz, Gregory G and Du, Weiming and Szarek, Michael and Bhatt, Deepak L and Bittner, Vera A and Budaj, Andrzej J and Diaz, Rafael and Goodman, Shaun G and Jukema, J Wouter and Kiss, Robert G and Harrington, Robert A and Moriarty, Patrick M and Scemama, Michel and Manvelian, Garen and Pordy, Robert and White, Harvey D and Zeiher, Andreas M and Fazio, Sergio and Geba, Gregory P and Steg, Ph Gabriel and ODYSSEY OUTCOMES Investigators, ODYSSEY OUTCOMES Investigators},
  title = {Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome},
  journal = {Journal of the American College of Cardiology},
  year = {2024},
  volume = {84},
  number = {11},
  pages = {994--1006},
  doi = {10.1016/j.jacc.2024.06.035}
}
Kostenlos starten →